ID   MCF-7:CFR
AC   CVCL_C5RV
SY   MCF7:CFR
DR   ChEMBL-Cells; CHEMBL4630713
DR   Wikidata; Q116049774
RX   PubMed=32453591;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:31638; Fulvestrant (ICI 182780).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C4194; Invasive breast carcinoma of no special type
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_DC70 ! MCF-7.5C
SX   Female
AG   69Y
CA   Cancer cell line
DT   Created: 15-12-22; Last updated: 29-06-23; Version: 3
//
RX   PubMed=32453591; DOI=10.1021/acs.jmedchem.0c00456; PMCID=PMC8258866;
RA   Li Y.-F., Zhao J., Gutgesell L.M., Shen Z.-N., Ratia K., Dye K.,
RA   Dubrovskyi O., Zhao H.-P., Huang F., Tonetti D.A., Thatcher G.R.J.,
RA   Xiong R.;
RT   "Novel pyrrolopyridone bromodomain and extra-terminal motif (BET)
RT   inhibitors effective in endocrine-resistant ER+ breast cancer with
RT   acquired resistance to fulvestrant and palbociclib.";
RL   J. Med. Chem. 63:7186-7210(2020).
//